Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.12.2018 | Case report

Dasabuvir/ombitasvir/paritaprevir/ritonavir/sorafenib

Various toxicities: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Revuelta-Herrero JL, et al. Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. Journal of Clinical Pharmacy and Therapeutics 43: 906-909, No. 6, Dec 2018. Available from: URL: http://doi.org/10.1111/jcpt.12727 - Spain Revuelta-Herrero JL, et al. Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. Journal of Clinical Pharmacy and Therapeutics 43: 906-909, No. 6, Dec 2018. Available from: URL: http://​doi.​org/​10.​1111/​jcpt.​12727 - Spain
Metadaten
Titel
Dasabuvir/ombitasvir/paritaprevir/ritonavir/sorafenib
Various toxicities: 3 case reports
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-55013-9

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe